Aurobindo Pharma Regulatory Approval
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received marketing authorization (NOC) from Health Canada for its Bevacizumab biosimilar, Bevqolva™. This regulatory approval follows earlier UK authorization and commercial launch. The biosimilar, used to treat colorectal and lung cancers, will be available in 100 mg and 400 mg formulations, strengthening Aurobindo's global biosimilar portfolio.